Search Results - "Altan, Mehmet"

Differential Expression and Significance of PD-L1, IDO-1, and B7-H4 in Human Lung Cancer by Schalper, Kurt A, Carvajal-Hausdorf, Daniel, McLaughlin, Joseph, Altan, Mehmet, Velcheti, Vamsidhar, Gaule, Patricia, Sanmamed, Miguel F, Chen, Lieping, Herbst, Roy S, Rimm, David L

“…To determine the expression level, associations, and biological role of PD-L1, IDO-1, and B7-H4 in non-small cell lung cancer (NSCLC). Using multiplexed…”
Get full text

Hyperspectral Image Classification via Basic Thresholding Classifier by Toksoz, Mehmet Altan, Ulusoy, Ilkay

“…We propose a lightweight sparsity-based algorithm, namely, the basic thresholding classifier (BTC), for hyperspectral image (HSI) classification. BTC is a…”
Get full text

Hyperspectral Image Classification via Kernel Basic Thresholding Classifier by Toksoz, Mehmet Altan, Ulusoy, Ilkay

“…We propose a nonlinear kernel version of recently introduced basic thresholding classifier (BTC) for hyperspectral image (HSI) classification. BTC is a…”
Get full text

B7-H3 Expression in NSCLC and Its Association with B7-H4, PD-L1 and Tumor-Infiltrating Lymphocytes by Altan, Mehmet, Pelekanou, Vasiliki, Schalper, Kurt A, Toki, Maria, Gaule, Patricia, Syrigos, Konstantinos, Herbst, Roy S, Rimm, David L

“…The immune checkpoint PD-1 and its receptor B7-H1 (PD-L1) are successful therapeutic targets in cancer but less is known about other B7 family members. Here,…”
Get full text

Mechanisms and clinical activity of an EGFR and HER2 exon 20–selective kinase inhibitor in non–small cell lung cancer by Robichaux, Jacqulyne P., Elamin, Yasir Y., Tan, Zhi, Carter, Brett W., Zhang, Shuxing, Liu, Shengwu, Li, Shuai, Chen, Ting, Poteete, Alissa, Estrada-Bernal, Adriana, Le, Anh T., Truini, Anna, Nilsson, Monique B., Sun, Huiying, Roarty, Emily, Goldberg, Sarah B., Brahmer, Julie R., Altan, Mehmet, Lu, Charles, Papadimitrakopoulou, Vassiliki, Politi, Katerina, Doebele, Robert C., Wong, Kwok-Kin, Heymach, John V.

“…Although most activating mutations of epidermal growth factor receptor (EGFR)-mutant non–small cell lung cancers (NSCLCs) are sensitive to available EGFR…”
Get full text

Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status by Ricciuti, Biagio, Arbour, Kathryn C, Lin, Jessica J, Vajdi, Amir, Vokes, Natalie, Hong, Lingzhi, Zhang, Jianjun, Tolstorukov, Michael Y, Li, Yvonne Y, Spurr, Liam F, Cherniack, Andrew D, Recondo, Gonzalo, Lamberti, Giuseppe, Wang, Xinan, Venkatraman, Deepti, Alessi, Joao V, Vaz, Victor R, Rizvi, Hira, Egger, Jacklynn, Plodkowski, Andrew J, Khosrowjerdi, Sara, Digumarthy, Subba, Park, Hyesun, Vaz, Nuno, Nishino, Mizuki, Sholl, Lynette M, Barbie, David, Altan, Mehmet, Heymach, John V, Skoulidis, Ferdinandos, Gainor, Justin F, Hellmann, Matthew D, Awad, Mark M

“…STK11 and KEAP1 mutations (STK11 mutant [STK11 ] and KEAP1 ) are among the most often mutated genes in lung adenocarcinoma (LUAD). Although STK11 has been…”
Get more information

S1778 IL12/23 Blockade Therapy for Refractory Immune Checkpoint Inhibitor Colitis: A Case Series by Thomas, Anusha Shirwaikar, McQuade, Jennifer, Altan, Mehmet, Wang, Yinghong

Get full text

S1782 Effect of PD-1/PD-L1 and Statin Combination Therapy on Gastrointestinal Toxicity Related to Immune Checkpoint Inhibitors and on Survival by Shah, Jay S., Rivera, Andres Urias, Mathew, Antony, Thomas, Anusha, Zhang, Hao Chi, Altan, Mehmet, Zhao, Dan, Wang, Yinghong

Get full text

Effect of neoadjuvant chemotherapy on tumor-infiltrating lymphocytes and PD-L1 expression in breast cancer and its clinical significance by Pelekanou, Vasiliki, Carvajal-Hausdorf, Daniel E, Altan, Mehmet, Wasserman, Brad, Carvajal-Hausdorf, Cristobal, Wimberly, Hallie, Brown, Jason, Lannin, Donald, Pusztai, Lajos, Rimm, David L

“…The effects of neoadjuvant chemotherapy on immune markers remain largely unknown. The specific aim of this study was to assess stromal tumor-infiltrating…”
Get full text

Pembrolizumab with or without radiation therapy for metastatic non-small cell lung cancer: a randomized phase I/II trial by Welsh, James, Menon, Hari, Chen, Dawei, Verma, Vivek, Tang, Chad, Altan, Mehmet, Hess, Kenneth, de Groot, Patricia, Nguyen, Quynh-Nhu, Varghese, Rejani, Comeaux, Nathan I, Simon, George, Skoulidis, Ferdinandos, Chang, Joe Y, Papdimitrakopoulou, Vasiliki, Lin, Steven H, Heymach, John V

“…BackgroundIn this phase I/II trial, we evaluated the safety and effectiveness of pembrolizumab, with or without concurrent radiotherapy (RT), for lung and…”
Get full text

Role of Radiation Therapy in Modulation of the Tumor Stroma and Microenvironment by Menon, Hari, Ramapriyan, Rishab, Cushman, Taylor R, Verma, Vivek, Kim, Hans H, Schoenhals, Jonathan E, Atalar, Cemre, Selek, Ugur, Chun, Stephen G, Chang, Joe Y, Barsoumian, Hampartsoum B, Nguyen, Quynh-Nhu, Altan, Mehmet, Cortez, Maria A, Hahn, Stephen M, Welsh, James W

“…In recent decades, there has been substantial growth in our understanding of the immune system and its role in tumor growth and overall survival. A central…”
Get full text

Poziotinib for EGFR exon 20-mutant NSCLC: Clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivity by Elamin, Yasir Y., Robichaux, Jacqulyne P., Carter, Brett W., Altan, Mehmet, Tran, Hai, Gibbons, Don L., Heeke, Simon, Fossella, Frank V., Lam, Vincent K., Le, Xiuning, Negrao, Marcelo V., Nilsson, Monique B., Patel, Anisha, Vijayan, R.S.K., Cross, Jason B., Zhang, Jianjun, Byers, Lauren A., Lu, Charles, Cascone, Tina, Feng, Lei, Luthra, Rajyalakshmi, San Lucas, Francis A., Mantha, Geeta, Routbort, Mark, Blumenschein, George, Tsao, Anne S., Heymach, John V.

“…We report a phase II study of 50 advanced non-small cell lung cancer (NSCLC) patients with point mutations or insertions in EGFR exon 20 treated with…”
Get full text

Early introduction of selective immunosuppressive therapy associated with favorable clinical outcomes in patients with immune checkpoint inhibitor-induced colitis by Abu-Sbeih, Hamzah, Ali, Faisal S, Wang, Xuemei, Mallepally, Niharika, Chen, Ellie, Altan, Mehmet, Bresalier, Robert S, Charabaty, Aline, Dadu, Ramona, Jazaeri, Amir, Lashner, Bret, Wang, Yinghong

“…Current treatment guidelines for immune-mediated colitis (IMC) recommend 4 to 6 weeks of steroids as first-line therapy, followed by selective…”
Get full text

Expression and clinical significance of PD-L1, B7-H3, B7-H4 and TILs in human small cell lung Cancer (SCLC) by Carvajal-Hausdorf, Daniel, Altan, Mehmet, Velcheti, Vamsidhar, Gettinger, Scott N, Herbst, Roy S, Rimm, David L, Schalper, Kurt A

“…Small cell lung cancer (SCLC) accounts for 10-15% of all lung malignancies and its prognosis is dismal. Although early studies have shown promising clinical…”
Get full text

Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy by Kim, Sang T., Chu, Yanshuo, Misoi, Mercy, Suarez-Almazor, Maria E., Tayar, Jean H., Lu, Huifang, Buni, Maryam, Kramer, Jordan, Rodriguez, Emma, Hussain, Zulekha, Neelapu, Sattva S., Wang, Jennifer, Shah, Amishi Y., Tannir, Nizar M., Campbell, Matthew T., Gibbons, Don L., Cascone, Tina, Lu, Charles, Blumenschein, George R., Altan, Mehmet, Lim, Bora, Valero, Vincente, Loghin, Monica E., Tu, Janet, Westin, Shannon N., Naing, Aung, Garcia-Manero, Guillermo, Abdel-Wahab, Noha, Tawbi, Hussein A., Hwu, Patrick, Oliva, Isabella C. Glitza, Davies, Michael A., Patel, Sapna P., Zou, Jun, Futreal, Andrew, Diab, Adi, Wang, Linghua, Nurieva, Roza

“…Immune checkpoint inhibitors are associated with immune-related adverse events (irAEs), including arthritis (arthritis-irAE). Management of arthritis-irAE is…”
Get full text

S185 Characteristics and Outcomes of Cancer Patients With Pre-existing Microscopic Colitis After Exposure to Immune Checkpoint Inhibitors by Thomas, Austin R., Liu, Cynthia, Tong, Yi Tat, Tan, Dongfeng, Altan, Mehmet, Siddiqui, Bilal A., Khan, Anam, Thomas, Anusha S., Wang, Yinghong

Get full text

Predicting response and toxicity to immune checkpoint inhibitors in lung cancer using antibodies to frameshift neoantigens by Shen, Luhui, Brown, Justin R, Johnston, Stephen Albert, Altan, Mehmet, Sykes, Kathryn F

“…To evaluate a new class of blood-based biomarkers, anti-frameshift peptide antibodies, for predicting both tumor responses and adverse immune events to immune…”
Get full text

Clinical characteristics and outcomes of immune checkpoint inhibitor-induced pancreatic injury by Abu-Sbeih, Hamzah, Tang, Tenglong, Lu, Yang, Thirumurthi, Selvi, Altan, Mehmet, Jazaeri, Amir A, Dadu, Ramona, Coronel, Emmanuel, Wang, Yinghong

“…Immune checkpoint inhibitor (ICI)-induced pancreatic injury (ICIPI) is not well documented in the literature. We aimed to describe the clinical characteristics…”
Get full text

Cutaneous Toxicities in Lung Cancer Patients on Immune Checkpoint Inhibitor Therapy by Keiser, Monika F., Patel, Anisha B., Altan, Mehmet

“…Immune checkpoint inhibitors (ICPIs) have transformed the treatment of lung cancer in the recent years. However, disruption in immune homeostasis produces a…”
Get full text

S203 Clinical Characteristics and Outcomes of Tyrosine Kinase Inhibitor-Related Lower GI Toxicities by Amin, Rajan, Panneerselvam, Kavea, Shah, Amishi Y., Altan, Mehmet, Thomas, Anusha Shirwaikar, Okhuysen, Pablo C., Wang, Yinghong

Get full text